Cartesian Therapeutics Inc
RNAC12.225USD
-0.105-0.85%
Market hours （ET）Quotes delayed by 15 min
317.07MMarket Cap
LossP/E TTM
More Details of Cartesian Therapeutics Inc Company
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Company Info
Ticker SymbolRNAC
Company nameCartesian Therapeutics Inc
IPO dateJun 22, 2016
CEODr. Carsten Brunn, Ph.D.
Number of employees66
Security typeOrdinary Share
Fiscal year-endJun 22
Address7495 New Horizon Way
CityFREDERICK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code21703
Phone13013488698
Websitehttps://www.cartesiantherapeutics.com/
Ticker SymbolRNAC
IPO dateJun 22, 2016
CEODr. Carsten Brunn, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Independent Director
Independent Director
3.82K
-14.03%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
--
-100.00%
Dr. Michael S. Singer, M.D., Ph.D.
Dr. Michael S. Singer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Independent Director
Independent Director
3.82K
-14.03%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Springer Timothy A
33.28%
Seven One Eight Three Four Irrevocable Trust
17.55%
Fidelity Management & Research Company LLC
9.02%
MPM BioImpact LLC
3.05%
Singer (Michael S.)
2.72%
Other
34.38%
Shareholders
Shareholders
Proportion
Springer Timothy A
33.28%
Seven One Eight Three Four Irrevocable Trust
17.55%
Fidelity Management & Research Company LLC
9.02%
MPM BioImpact LLC
3.05%
Singer (Michael S.)
2.72%
Other
34.38%
Shareholder Types
Shareholders
Proportion
Individual Investor
39.94%
Corporation
20.08%
Investment Advisor
18.12%
Investment Advisor/Hedge Fund
5.70%
Hedge Fund
1.47%
Research Firm
0.19%
Insurance Company
0.10%
Bank and Trust
0.10%
Pension Fund
0.03%
Other
14.26%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
206
22.28M
85.84%
-1.26M
2025Q1
226
22.94M
90.08%
+138.68K
2024Q4
230
22.26M
88.90%
-105.22K
2024Q3
229
20.22M
92.77%
+6.58M
2024Q2
235
14.41M
85.20%
+9.02M
2024Q1
233
3.74M
346.71%
-1.42M
2023Q4
240
3.82M
71.00%
-922.87K
2023Q3
251
3.63M
70.60%
-1.17M
2023Q2
261
3.72M
72.70%
-649.68K
2023Q1
272
3.43M
67.38%
-196.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Springer Timothy A
8.64M
33.28%
+22.36K
+0.26%
Apr 14, 2025
Seven One Eight Three Four Irrevocable Trust
4.56M
17.55%
--
--
Apr 14, 2025
Fidelity Management & Research Company LLC
2.34M
9.02%
-83.30K
-3.44%
Mar 31, 2025
MPM BioImpact LLC
790.78K
3.05%
+69.64K
+9.66%
Mar 31, 2025
Singer (Michael S.)
707.06K
2.72%
-623.00
-0.09%
Apr 14, 2025
TAS Partners, L.L.C.
656.51K
2.53%
+126.72K
+23.92%
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
608.03K
2.34%
+1.49K
+0.25%
Mar 31, 2025
Invus Public Equities Advisors, LLC
563.27K
2.17%
-8.96K
-1.57%
Mar 31, 2025
The Vanguard Group, Inc.
503.54K
1.94%
+74.06K
+17.24%
Mar 31, 2025
Kalayoglu (Murat)
502.42K
1.94%
-8.88K
-1.74%
Apr 14, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ALPS Medical Breakthroughs ETF
0%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.91%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Date
Type
Ratio
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
